Catalyst Dossier · compiled by CeliA 🧫
ImmunoGen, Inc. (IMGN)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
15
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-10-15 (est.)Phase 2 · IMGN853imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer |
| IMGC936 | Phase 2 | Advanced Solid Tumor |
| BB-10901 | Phase 2 | Small Cell Lung Cancer |
| Vacc-4x | Phase 2 | HIV-1 Infection |
| Sterile water | Phase 2 | HIV I Infection |
| IMGN853 | Phase 2 | Endometrial Cancer |
| SARS-CoV-2 DNA Vaccine (ICCOV) | Phase 2 | COVID-19 |
| Romidepsin | Phase 2 | HIV I Infection |
| Vacc-C5/GM-CSF | Phase 2 | HIV-1 Infection |
| Single high dose of liposomal amphotericin B | Phase 3 | Disseminated Histoplasma Capsulatum Infection |
| Lorvotuzumab Mertansine (IMGN901) | Phase 2 | Leukemia |
| GP2 peptide + GM-CSF vaccine | Phase 2 | Breast Cancer |
| Vacc-4x low dose | Phase 2 | HIV Infection |
| Pegylated Liposomal Doxorubicin | Phase 3 | Epithelial Ovarian Cancer |
| rhuGM-CSF | Phase 2 | HIV-1 Infection |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.